OptimizeRx (NASDAQ:OPRX) Price Target Raised to $11.00 at Citizens Jmp

OptimizeRx (NASDAQ:OPRX) had its price target boosted by Citizens Jmp from $9.00 to $11.00 in a research note released on Friday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

A number of other brokerages have also commented on OPRX. B. Riley Financial dropped their price objective on shares of OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of OptimizeRx in a report on Tuesday. Citigroup reissued a “market outperform” rating on shares of OptimizeRx in a research note on Friday. UBS Group set a $11.00 price target on OptimizeRx in a report on Friday. Finally, Zacks Research cut OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 4th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.43.

OptimizeRx Price Performance

Shares of OPRX opened at $8.72 on Friday. The stock has a 50 day simple moving average of $6.11 and a 200 day simple moving average of $6.73. OptimizeRx has a 52-week low of $4.54 and a 52-week high of $22.25. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.37 and a current ratio of 5.58. The firm has a market capitalization of $163.63 million, a PE ratio of 37.91 and a beta of 1.08.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.11 by $0.05. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The firm had revenue of $20.50 million for the quarter, compared to the consensus estimate of $20.20 million. Sell-side analysts predict that OptimizeRx will post 0.51 EPS for the current fiscal year.

Hedge Funds Weigh In On OptimizeRx

Several hedge funds and other institutional investors have recently made changes to their positions in OPRX. Next Century Growth Investors LLC grew its position in shares of OptimizeRx by 139.8% in the 4th quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock valued at $6,196,000 after acquiring an additional 294,688 shares during the period. Manatuck Hill Partners LLC raised its holdings in shares of OptimizeRx by 139.5% in the 2nd quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock valued at $6,142,000 after purchasing an additional 265,000 shares during the period. AWM Investment Company Inc. acquired a new stake in OptimizeRx in the 2nd quarter valued at about $1,375,000. Kennedy Capital Management LLC lifted its stake in OptimizeRx by 42.8% in the 3rd quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock valued at $13,836,000 after purchasing an additional 202,446 shares during the last quarter. Finally, Invesco Ltd. bought a new position in OptimizeRx during the third quarter worth about $4,081,000. 76.47% of the stock is owned by institutional investors.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.